PharmaCielo (TSE:PCLO)
:PCLO
Want to see TSE:PCLO full AI Analyst Report?
PCLO Stock Chart & Stats
C$0.04
<C$0.01(5.56%)
At close: 4:00 PM EST
C$0.04
<C$0.01(5.56%)
Day’s Range― - ―
52-Week RangeC$0.04 - C$0.17
Previous CloseN/A
Volume2.00K
Average Volume (3M)0.00
Market Cap
C$11.54M
Enterprise ValueC$34.34M
Total Cash (Recent Filing)C$289.24K
Total Debt (Recent Filing)C$18.65M
Price to Earnings (P/E)―
Beta-3.09
Next Earnings
Aug 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding187,983,690
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.55
Price to Sales (P/S)3.24
P/FCF Ratio-8.30
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
B2B Standardized Cannabinoid SupplierPharmaCielo’s focus on standardized cannabinoid ingredients for medical and wellness customers is a durable B2B model. Supplying regulated, quality-controlled inputs can create long-term institutional relationships and barriers for new entrants, supporting recurring demand if regulatory access persists.
Positive Product-level Gross MarginsA positive gross margin (~29%) indicates the core extraction and processing operations generate product economics before overhead. If scale or utilization improves, these unit-level margins offer a pathway to absorb SG&A and move toward operating breakeven as revenue stabilizes or grows.
Operational Improvement TrendReported cash-flow and margin improvements versus the extreme losses of 2020–2023 demonstrate management progress on cost control and operations. Persistent execution on these trends can strengthen liquidity and reduce reliance on external financing over a 2–6 month horizon.
Bears Say
Severely Stressed Balance SheetNegative equity and debt materially above reported assets signal solvency and refinancing risk. This highly leveraged capital structure constrains strategic flexibility, increases default risk if cash generation falters, and may force dilutive recapitalizations or asset sales.
Ongoing Cash BurnPersistent negative OCF and FCF mean the company still consumes cash to operate. Even with improvement, continued burn requires external funding for debt service, working capital, or reinvestment, exposing the business to funding availability and raising long-term execution risk.
Weak, Declining Revenue And Deep LossesDeclining, volatile top-line alongside very large operating and net losses show the revenue base is insufficient to cover fixed costs. Without sustained revenue recovery or substantial cost restructuring, achieving sustainable profitability remains unlikely over the medium term.
PharmaCielo News
PCLO FAQ
What was PharmaCielo’s price range in the past 12 months?
PharmaCielo lowest stock price was C$0.04 and its highest was C$0.17 in the past 12 months.
What is PharmaCielo’s market cap?
PharmaCielo’s market cap is C$11.54M.
When is PharmaCielo’s upcoming earnings report date?
PharmaCielo’s upcoming earnings report date is Aug 14, 2026 which is in 70 days.
How were PharmaCielo’s earnings last quarter?
Currently, no data Available
Is PharmaCielo overvalued?
According to Wall Street analysts PharmaCielo’s price is currently Overvalued.
Does PharmaCielo pay dividends?
PharmaCielo does not currently pay dividends.
What is PharmaCielo’s EPS estimate?
PharmaCielo’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaCielo have?
PharmaCielo has 187,983,690 shares outstanding.
What happened to PharmaCielo’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmaCielo?
Currently, no hedge funds are holding shares in TSE:PCLO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaCielo
PharmaCielo Ltd., together with its subsidiary, cultivates, processes, produces, and supplies medicinal-grade cannabis extracts, tetrahydrocannabinol, and related products. The company also offers telemedicine software. It serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies in Canada and Colombia. The company has a strategic alliance with AssuredTrans Inc. PharmaCielo Ltd. is headquartered in Toronto, Canada.
Technical Analysis
Willow Biosciences Inc
―
MediPharm Labs
―
Nextleaf Solutions
―
Avicanna
―
InnoCan Pharma
―
Options Prices
Currently, No data available
---